ReviewEuropean journal of nuclear medicine and molecular imaging2018
Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.
Review in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Seronegative Autoimmune Encephalitis With Neuropsychiatric Presentation: A Case Report.Cureus · 2026Article
- Advance and Prospect of Positron Emission Tomography in Alzheimer's disease research.Molecular psychiatry · 2025Review
- A metabolism-functional connectome sparse coupling method to reveal imaging markers for Alzheimer's disease based on simultaneous PET/MRI scans.Human brain mapping · 2023Article
- Generation of ConventionalMedicina (Kaunas, Lithuania) · 2023Article
- Review
- Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer's disease?Frontiers in aging neuroscience · 2023Review
- Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study.Molecular neurobiology · 2022Article
- Neuroimaging Modalities in Alzheimer's Disease: Diagnosis and Clinical Features.International journal of molecular sciences · 2022Review
- Long-term running exercise improves cognitive function and promotes microglial glucose metabolism and morphological plasticity in the hippocampus of APP/PS1 mice.Journal of neuroinflammation · 2022Article
- Comparison of [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring.International journal of molecular sciences · 2021Review
- Single and Combined Neuroimaging Techniques for Alzheimer's Disease Detection.Computational intelligence and neuroscience · 2021Review
- Characterizing the heterogeneous metabolic progression in idiopathic REM sleep behavior disorder.NeuroImage. Clinical · 2020Article
- Consequences of Metabolic Disruption in Alzheimer's Disease Pathology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Review
- Neuroimaging and Neurolaw: Drawing the Future of Aging.Frontiers in endocrinology · 2019Review
- Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.European journal of nuclear medicine and molecular imaging · 2018Review
- Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia.European journal of nuclear medicine and molecular imaging · 2018Article
- Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.European journal of nuclear medicine and molecular imaging · 2018Review
- Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia.European journal of nuclear medicine and molecular imaging · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the clinical utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of early signs of neurodegeneration in conditions of increased risk for Alzheimer's disease (AD) as defined by: subjective cognitive decline (SCD), evidence of cerebral amyloid-pathology, apolipoprotein E (APOE) ε4-positive genotype, or autosomal dominant forms of AD (ADAD) in asymptomatic stages.
methodsA comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted using the Delphi method on three different diagnostic scenarios.
resultsThe level of empirical study evidence for the use of FDG-PET to detect meaningful early signs of neurodegeneration was considered to be poor for ADAD and lacking for SCD and asymptomatic persons at risk, based on APOE ε4-positive genotype or cerebral amyloid pathology. Consequently, and consistent with current diagnostic criteria, panelists decided not to recommend routine clinical use of FDG-PET in these situations and to currently mainly reserve it for research purposes.
conclusionCurrently, there is limited evidence on which to base recommendations regarding the clinical routine use of FDG-PET to detect diagnostically meaningful early signs of neurodegeneration in asymptomatic subjects with ADAD, with APOE ε4-positive genotype, or with cerebral amyloid pathology, and in subjects with SCD. Future prospective studies are warranted and in part already ongoing, aiming to assess the added value of FDG-PET in this context beyond research applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.